BIO-TECHNE grants Julie L. Bushman 2,750 shares

Q: How many TECH shares did director Julie L. Bushman receive?

Julie L. Bushman received a grant/award of 2,750 common shares on October 29, 2026. Her directly held common-stock position following the transaction was 11,525 shares.

One direct option position listed for the director covers 6,028 underlying shares at a $63.9200 exercise price and expires October 29, 2030.

Available on EDGAR 11/02/2026 - 04:14 PM EST Accepted by SEC EDGAR 11/02/2026 - 04:14 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

BIO-TECHNE Corp director Julie L. Bushman received a grant/award of 2,750 common shares on October 29, 2026; her directly held common-stock position following the transaction was 11,525 shares. Her direct stock-option holdings listed as of October 29, 2026, comprise seven positions, with underlying share amounts of 1,444 to 6,028, exercise prices of $60.9600 to $128.8100, and expiration dates from July 31, 2030, through October 30, 2035.

Insider Trade Summary

Grant/Award: 2,750 shares

Grant/Award 1 txn

Insider Bushman Julie L

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,750	$0.00	$0.00
Holding	Stock Options (Right to Buy)	--	--	--
Holding	Stock Options (Right to Buy)	--	--	--
Holding	Stock Options (Right to Buy)	--	--	--
Holding	Stock Options (Right to Buy)	--	--	--
Holding	Stock Options (Right to Buy)	--	--	--
Holding	Stock Options (Right to Buy)	--	--	--
Holding	Stock Options (Right to Buy)	--	--	--

Holdings After Transaction: Common Stock — 11,525 shares (Direct); Stock Options (Right to Buy) — 24,689 contracts (Direct)

Key Figures

Common shares acquired: 2,750 shares Direct common-stock holdings following transaction: 11,525 shares Underlying shares in direct option positions: 1,444–6,028 shares per position +1 more

4 metrics

Common shares acquired 2,750 shares Grant/award on October 29, 2026

Direct common-stock holdings following transaction 11,525 shares After the October 29, 2026, grant/award

Underlying shares in direct option positions 1,444–6,028 shares per position Seven positions listed as of October 29, 2026

Exercise prices for direct option positions $60.9600–$128.8100 Seven positions listed as of October 29, 2026

Key Terms

Stock Options (Right to Buy), exercise price, expiration date

3 terms

Stock Options (Right to Buy) financial

"Stock Options (Right to Buy) for Common Stock"

exercise price financial

"options with a $63.9200 exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"October 29, 2030 expiration date"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TECH shares did director Julie L. Bushman receive?

Julie L. Bushman received a grant/award of 2,750 common shares on October 29, 2026. Her directly held common-stock position following the transaction was 11,525 shares.

What TECH stock options does Julie L. Bushman hold?

As of October 29, 2026, seven direct stock-option positions are listed: 1,444 underlying shares at $69.7200, expiring July 31, 2030; 6,028 at $63.9200, expiring October 29, 2030; 2,532 at $128.8100, expiring October 28, 2031; 3,460 at $73.9400, expiring October 27, 2032; 3,937 at $61.5100, expiring October 26, 2033; 3,511 at $68.3700, expiring October 24, 2034; and 3,777 at $60.9600, expiring October 30, 2035.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bushman Julie L

(Last)

(First)

(Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS

MINNESOTA

55413

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/29/2026		A		2,750	A	$0	11,525	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to Buy)	$69.72							10/29/2021	07/31/2030	Common Stock	1,444		1,444	D
Stock Options (Right to Buy)	$63.92							10/28/2021	10/29/2030	Common Stock	6,028		6,028	D
Stock Options (Right to Buy)	$128.81							10/27/2022	10/28/2031	Common Stock	2,532		2,532	D
Stock Options (Right to Buy)	$73.94							10/26/2023	10/27/2032	Common Stock	3,460		3,460	D
Stock Options (Right to Buy)	$61.51							10/24/2024	10/26/2033	Common Stock	3,937		3,937	D
Stock Options (Right to Buy)	$68.37							10/24/2025	10/24/2034	Common Stock	3,511		3,511	D
Stock Options (Right to Buy)	$60.96							10/29/2026	10/30/2035	Common Stock	3,777		3,777	D

Explanation of Responses:

	/s/ Andrew Nick as Attorney-in-Fact for Julie Bushman pursuant to Power of Attorney previously filed.	11/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR